Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Sara E. Williford"'
Autor:
Christina L. Burch, Shuntai Zhou, Paul Ingravallo, Ernest Asante-Appiah, Ronald Swanstrom, Tiffany Benzine, Anita Y. M. Howe, David R. McGivern, Stanley M. Lemon, Sara E. Williford, Fengyu Hu
Direct-acting antivirals (DAAs) targeting NS5A are broadly effective against hepatitis C virus (HCV) infections, but sustained virological response rates are generally lower in patients infected with genotype (gt)-1a than gt-1b viruses. The explanati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4b71f03e50ae39f041e884ffc3d3e617
https://europepmc.org/articles/PMC6146077/
https://europepmc.org/articles/PMC6146077/
Autor:
Stanley M. Lemon, Kevin M. Weeks, David M. Mauger, Sara E. Williford, Daisuke Yamane, Michael Golden, Darren P. Martin
Publikováno v:
Proceedings of the National Academy of Sciences. 112:3692-3697
Hepatitis C virus (HCV) infects over 170 million people worldwide and is a leading cause of liver disease and cancer. The virus has a 9,650-nt, single-stranded, messenger-sense RNA genome that is infectious as an independent entity. The RNA genome ha
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0ae61682b1f0d2b5ba8c680b5e32a5a4
https://doi.org/10.1073/pnas.1416266112
https://doi.org/10.1073/pnas.1416266112
Autor:
Sara E. Williford, Stanley M. Lemon
Publikováno v:
Clinical Virology ISBN: 9781683670674
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5e8c434a61ddc4fdb66b2ebb27cfa29a
https://doi.org/10.1128/9781555819439.ch48
https://doi.org/10.1128/9781555819439.ch48
Autor:
Sara E. Williford, David R. McGivern
Publikováno v:
Hepatitis C Virus II ISBN: 9784431560999
The urgent need for novel therapeutics to address the burden of disease associated with chronic hepatitis C has driven the development of direct-acting antivirals (DAA) that target hepatitis C virus (HCV) replication. Combination therapies targeting
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2b0aafc8286c08e9cd888d08d66b0fa1
https://doi.org/10.1007/978-4-431-56101-9_11
https://doi.org/10.1007/978-4-431-56101-9_11
Autor:
Sara E. Williford, Cassandra B. Jabara, Corbin D. Jones, Fengyu Hu, Katie R. Mollan, Prema Menezes, Michael G. Hudgens, Yan Yang, Ronald Swanstrom, Stanley M. Lemon, Michael W. Fried, Joseph J. Eron
Publikováno v:
Antimicrobial agents and chemotherapy. 58(10)
HIV coinfection accelerates disease progression in chronic hepatitis C and reduces sustained antiviral responses (SVR) to interferon-based therapy. New direct-acting antivirals (DAAs) promise higher SVR rates, but the selection of preexisting resista
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c218aa32392f6d993668fc0f00451c5b
https://pubmed.ncbi.nlm.nih.gov/25092699
https://pubmed.ncbi.nlm.nih.gov/25092699
Autor:
Ernest Asante-Appiah, David R. McGivern, Sara E. Williford, Takahiro Masaki, Petra Neddermann, Frederick C. Lahser, Zongdi Feng, Stanley M. Lemon, Raffaele De Francesco, Anita Y. M. Howe, Paul Ingravallo
All-oral regimens combining different classes of direct-acting antivirals (DAA) are highly effective for treatment of patients with chronic hepatitis C. NS5A inhibitors will likely form a component of future interferon-sparing treatment regimens. How
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6f25661fecd6d13dbb2405a47dac9183